Product Description
Captopril USP Pharmaceutical Cardiovascular drugs made in china 62571-86-2
AI Product Description
*The following content is generated by AI and is for reference only.
Captopril, designated as Captopril USP, is a pioneering pharmaceutical agent manufactured in China and globally recognized for its pivotal role in cardiovascular therapeutics. As the first orally active angiotensin-converting enzyme (ACE) inhibitor developed for clinical use, it serves as a cornerstone medication in managing hypertension, heart failure, and diabetic nephropathy. The chemical structure of Captopril is defined by the molecular formula C9H15NO3S, with a corresponding CAS number of 62571-86-2. This unique molecule features a sulfhydryl group that distinguishes it from later-generation ACE inhibitors, allowing it to bind effectively to the zinc ion at the active site of the enzyme, thereby blocking the conversion of angiotensin I to the potent vasoconstrictor angiotensin II.
Produced under strict United States Pharmacopeia (USP) standards by leading Chinese pharmaceutical manufacturers, Captopril ensures high purity, consistent potency, and rigorous quality control essential for global distribution. Its therapeutic applications are extensive; it is primarily prescribed to lower blood pressure in patients with essential or renovascular hypertension, reducing the workload on the heart and preventing stroke risk. Furthermore, it is indicated for the treatment of congestive heart failure, where it improves survival rates and reduces hospitalization frequencies by decreasing systemic vascular resistance and preload. In diabetic patients, Captopril offers renal protection by mitigating proteinuria and slowing the progression of kidney disease associated with diabetes.
The drug is typically administered orally in tablet form, often starting at low doses to minimize side effects such as hypotension or cough, which are common among ACE inhibitors. While the sulfhydryl moiety can occasionally cause taste disturbances or skin rashes, its efficacy and cost-effectiveness make it a preferred choice in many healthcare systems, particularly in resource-limited settings. Continuous advancements in manufacturing processes within China have further optimized the supply chain, ensuring reliable availability of this life-saving cardiovascular drug for patients worldwide.